Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2018 16:01 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results

SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported...
April 16, 2018 07:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA

FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus...
April 04, 2018 16:01 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Closing of $3.55 Million Public Offering

SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
March 28, 2018 08:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
March 27, 2018 16:33 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Proposed Public Offering

SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
March 26, 2018 07:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
March 01, 2018 16:01 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call /...
February 21, 2018 07:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
February 16, 2018 07:00 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
November 02, 2017 16:01 ET | Source: Apricus Biosciences, Inc.

Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results

Vitaros U.S. NDA Resubmission Review Remains on TrackPDUFA Goal Date of February 17, 2018 Conference Call / Webcast Today, November 2, 2017 at 4:30 p.m. ET SAN DIEGO, Calif., Nov. 02, 2017 (GLOBE...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right